Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
Mark T. Reding,
Shadan Lalezari,
Gili Kenet,
Giovanni Di Minno,
Jonathan Ducore,
Alexander Solms,
Anita Shah,
Pål André Holme,
Lone H. Poulsen,
Karina Meijer,
Mindy Simpson,
Maria Elisa Mancuso
Affiliations
Mark T. Reding
Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center
Shadan Lalezari
National Hemophilia Center, Sheba Medical Center
Gili Kenet
National Hemophilia Center, Sheba Medical Center
Giovanni Di Minno
Regional Reference Center for Coagulation Disorders, Federico II University Hospital
Jonathan Ducore
Hemophilia Treatment Center, UC Davis Medical Center
Alexander Solms
Bayer AG
Anita Shah
Bayer
Pål André Holme
Department of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo
Lone H. Poulsen
The Haemophilia Centre, Aarhus University Hospital
Karina Meijer
University Medical Center Groningen
Mindy Simpson
Rush Hemophilia and Thrombophilia Center, Rush University Medical Center
Maria Elisa Mancuso
Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital
